From Yahoo Finance: 2025-05-29 13:50:00

Truist Securities initiated coverage on Teva Pharmaceutical Industries Limited (NYSE: TEVA) with a Buy rating and a price target of $25 on May 27. Teva is an Israeli pharmaceutical company specializing in generic drugs, branded medicines, and APIs. The company’s strategy of balancing high-margin branded products with generics is expected to drive sustainable growth.

Teva recently launched a $700 million cost-cutting initiative to enhance operational efficiency and achieve a 30% operating margin by 2027. Moody’s and Fitch upgraded the company’s credit rating due to its focus on debt reduction and profitable growth. Analysts believe Teva’s approach will support margin improvement and sustainable profitability.

While Teva shows potential as an investment, some believe AI stocks offer greater promise with limited downside risk. For those seeking AI stocks with potential for high returns, consider exploring reports on other options. Teva’s focus on debt reduction, cost-cutting, and profitable growth has garnered credit rating upgrades and is expected to drive margin improvement in the future.

Read more: Truist Initiates Teva Pharmaceuticals (TEVA) Coverage with Buy, $25 Price Target